12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Octapharma, Pfizer sales and marketing update

Octapharma granted Pfizer exclusive U.S. rights to commercialize prothrombin complex concentrate (PCC). PCC is under FDA review in the U.S. for reversal of...

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >